Analysts Are Bullish on Top Healthcare Picks

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intercept Pharma (NASDAQ: ICPT) and Adaptimmune Therapeutics (NASDAQ: ADAP) with bullish sentiments.

Intercept Pharma (NASDAQ: ICPT)

In a report released today, Ritu Baral from Cowen & Co. reiterated a Buy rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $225. The company’s shares opened today at $113.91.

Baral noted:

“While this year’s AASLD does not appear to have any major stock moving datasets,.”

According to TipRanks.com, Baral is a 4-star analyst with an average return of 6.2% and a 41.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on Intercept Pharma is Moderate Buy and the average price target is $218.13, representing a 91.5% upside.

In a report issued on November 3, Needham also reiterated a Buy rating on the stock with a $350 price target.
Adaptimmune Therapeutics (NASDAQ: ADAP)

In a report released today, Eric Schmidt from Cowen & Co. reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP). The company’s shares opened today at $5.20, close to its 52-week low of $3.76.

Schmidt wrote:

“At SITC, we hosted a dinner with senior management and a KOL.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 23.1% and a 57.8% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Currently, the analyst consensus on Adaptimmune Therapeutics is Strong Buy and the average price target is $15, representing a 188.5% upside.

In a report issued on November 11, Leerink Swann also reiterated a Buy rating on the stock with a $15 price target.